Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed Q4 fiscal 2025 revenue rises 10% to $1.3 billion; EPS $2.58; dividend raised to $0.60

Positive Impact 4 of 5 earnings Written later

ResMed reported fourth-quarter fiscal 2025 results for the quarter ended June 30, 2025, with revenue up 10% to $1.3 billion and diluted earnings per share up 30% to $2.58. The company also declared a quarterly dividend of $0.60 per share, a 13% increase, payable September 18, 2025 to holders of record on August 14, 2025.

Key points

  • Q4 revenue $1,348.0 million, up 10% (9% constant currency); income from operations up 19% to $454.5 million
  • Q4 diluted EPS $2.58 vs. $1.98 a year earlier; non-GAAP diluted EPS $2.55 vs. $2.08
  • Full-year revenue $5.1 billion, up 10%; full-year diluted EPS $9.51 vs. $6.92
  • Quarterly dividend $0.60 per share; ex-dividend date August 13, 2025

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECJul 31, 2025, 4:05 PM ET
Accession number0001193125-25-170512

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.